Revvity, Inc income statement RVTY

In Q2 of fiscal 2026, the quarter ended Jul 5, 2026, Revvity, Inc reported revenue of $729.7 million, up 1.3% from the same quarter a year earlier. Net income was $51.8 million, a profit margin of 7.1%. Operating income came to $89.3 million, an operating margin of 12.2%. Diluted earnings per share were $0.47.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jul 5, 2026
Q2 FY2026
Jul 5, 2026
Q1 FY2026
Apr 5, 2026
Q4 FY2025
Dec 28, 2025
Q3 FY2025
Sep 28, 2025
Q2 FY2025
Jun 29, 2025
Q1 FY2025
Mar 30, 2025
Q4 FY2024
Dec 29, 2024
Q3 FY2024
Sep 29, 2024
Revenue
2,912
+4.1%
730
+1.3%
711
+7.0%
772
+5.9%
699
+2.2%
720
+4.1%
665
+2.3%
729
+4.8%
684
+2.0%
Cost of revenue
—
313
-4.5%
323
+11.8%
—
324
+8.4%
328
+7.0%
289
-1.9%
—
299
+0.3%
Gross profit
—
417
+6.2%
388
+3.2%
—
375
-2.7%
393
+1.8%
376
+5.8%
—
385
+3.3%
Research and development
216
+5.2%
49
-8.1%
58
+8.0%
58
+18.2%
51
+3.4%
53
+10.7%
54
+6.4%
49
-0.8%
49
-7.3%
Selling, general and administrative
1,026
+4.7%
279
+12.1%
254
+1.7%
252
+3.0%
242
+1.8%
249
-1.2%
250
-4.2%
244
-4.8%
238
-5.1%
Operating expenses
—
328
+8.5%
312
+2.8%
—
293
+2.1%
302
+0.7%
303
-2.4%
—
287
-5.5%
Operating income
359
-5.5%
89
-1.6%
76
+5.1%
112
-5.9%
82
-16.6%
91
+5.9%
72
+63.7%
119
+53.9%
98
+41.8%
Other income (expense)
-98
-53.4%
-26
-16.6%
-26
-30.5%
-20
+16.5%
-26
-1288.2%
-22
-2457.1%
-20
-107.5%
-24
+47.2%
2
+111.8%
Pretax income
261
-17.5%
64
-7.5%
50
-4.6%
92
-3.2%
56
-44.5%
69
-20.8%
52
+51.6%
95
+201.3%
100
+98.3%
Income tax
23
-37.2%
10
-25.2%
9
-15.1%
-4
-168.2%
8
+21.4%
13
-4.5%
11
+83.0%
6
+119.2%
7
-61.6%
Net income
238
-16.7%
52
-3.9%
41
-3.6%
98
+3.9%
47
-50.6%
54
-2.6%
42
+62.4%
95
+20.5%
94
+893.7%
Basic EPS
2.10
-11.2%
0.47
+2.2%
0.36
+2.9%
0.87
+11.6%
0.40
-48.1%
0.46
+2.2%
0.35
+66.7%
0.78
+22.4%
0.77
+862.5%
Diluted EPS
2.10
-11.2%
0.47
+2.2%
0.36
+2.9%
0.87
+11.4%
0.40
-48.1%
0.46
+2.2%
0.35
+66.7%
0.78
+22.4%
0.77
+862.5%
Weighted average shares, basic
113
-6.2%
112
-5.0%
112
-6.9%
113
-6.8%
115
-6.0%
118
-4.7%
120
-2.7%
121
-1.5%
123
-1.0%
Weighted average shares, diluted
113
-6.2%
112
-5.0%
112
-7.0%
113
-6.7%
115
-6.1%
118
-4.8%
120
-2.7%
121
-1.6%
123
-0.9%
Other measures
Depreciation and amortization
412
-0.2%
102
-0.7%
105
+7.8%
103
-1.9%
102
-5.2%
103
-4.3%
97
-9.6%
105
-0.5%
108
-0.5%
EBITDA
771
-2.7%
191
-1.1%
181
+6.7%
215
-4.0%
184
-10.6%
194
+0.2%
170
+11.7%
224
+22.5%
206
+16.0%
Interest coverage
3.82x
3.88x
3.07x
4.75x
3.60x
3.96x
3.15x
5.21x
4.03x
Margins
Gross margin
—
57.13%
54.51%
—
53.60%
54.50%
56.49%
—
56.26%
Operating margin
12.32%
12.24%
10.67%
14.47%
11.72%
12.60%
10.87%
16.28%
14.35%
Pretax margin
8.96%
8.71%
7.03%
11.86%
7.97%
9.53%
7.88%
12.96%
14.67%
Profit margin
8.16%
7.10%
5.73%
12.74%
6.67%
7.49%
6.35%
12.98%
13.80%
EBITDA margin
26.48%
26.22%
25.44%
27.83%
26.32%
26.87%
25.52%
30.68%
30.09%
Effective tax rate
8.97%
15.82%
18.20%
-4.60%
15.20%
19.56%
20.45%
6.53%
6.95%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
RVTY (NYSE)
Fiscal year ends
December 29
Incorporated in
MA
Headquarters
Waltham, MA
SEC filer status
Large accelerated filer
SEC CIK
31791
Former names
PERKINELMER INC (until Apr 14, 2023); EG&G INC (until Jul 26, 1999)

Other Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.